Lung Cancer Market Size, Share, Growth, and Industry Analysis, By Type (Surgery, Chemotherapy, Radiotherapy, Photodynamic therapy (PDT), Laser therapy), By Application (Hospitals & Clinics, Cancer Research Centers, Laboratories), Regional Insights and Forecast to 2035

Lung Cancer Market Overview

Lung Cancer Market size is estimated at USD 38955.71 million in 2026 and expected to rise to USD 102716.3 million by 2035, experiencing a CAGR of 11.38%.

The Lung Cancer Market is experiencing substantial expansion due to the growing prevalence of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) across aging populations and high-risk smoking demographics. Lung Cancer Market Trends indicate that nearly 85% of diagnosed lung cancer cases globally are categorized as NSCLC, while advanced-stage diagnosis accounts for more than 60% of total identified cases. Increasing adoption of targeted therapy, precision diagnostics, immunotherapy combinations, and biomarker-based treatment approaches has accelerated clinical demand within the Lung Cancer Industry Analysis. More than 55% of oncology centers are integrating AI-supported imaging for early-stage tumor detection, while over 48% of hospitals have expanded low-dose CT screening programs. Lung Cancer Market Insights also reveal that hospital-based treatment settings dominate patient management due to multidisciplinary cancer care systems. The growing burden of environmental pollutants, occupational carcinogens, and tobacco exposure continues to support sustained demand across the Lung Cancer Market Research Report and Lung Cancer Market Forecast landscape.

The United States remains one of the most significant contributors to the Lung Cancer Market due to high screening penetration, advanced oncology infrastructure, and widespread adoption of personalized medicines. Approximately 13% of all newly diagnosed cancers in the country are linked to lung cancer, while nearly 80% of cases are associated with smoking history. More than 65% of oncology hospitals in the U.S. utilize biomarker testing before treatment selection, supporting demand for precision therapies and immunotherapy combinations. Around 58% of eligible adults have access to low-dose CT screening programs through healthcare networks and employer-backed insurance systems. Non-small cell lung cancer represents nearly 84% of diagnosed cases in the country. Over 45% of pharmaceutical clinical trials related to lung cancer therapies are conducted across U.S.-based research institutions, supporting innovation in targeted drugs, checkpoint inhibitors, and combination treatment protocols within the Lung Cancer Market Outlook.

Download FREE Sample to learn more about this report.

Key Findings

• Key Market Driver: More than 72% of diagnosed lung cancer patients require multimodal treatment approaches, while targeted therapy adoption increased by 48% among biomarker-positive patients, accelerating demand across oncology care systems and supporting continuous expansion in precision-based Lung Cancer Market Growth.
• Major Market Restraint: Approximately 41% of low-income patients face delayed diagnosis due to limited screening accessibility, while nearly 37% of healthcare facilities report shortages in advanced oncology infrastructure, restricting early treatment adoption and reducing overall therapeutic accessibility.
• Emerging Trends: Immunotherapy utilization increased by 54% in advanced-stage treatment protocols, while AI-assisted imaging adoption rose by 46% across diagnostic centers, significantly improving early tumor identification rates and strengthening innovation within the Lung Cancer Market Analysis.
• Regional Leadership: North America accounts for nearly 39% of global advanced oncology treatment implementation, while Asia-Pacific contributes over 44% of newly diagnosed patient populations, supporting strong regional activity across the Lung Cancer Industry Report landscape.
• Competitive Landscape: More than 63% of leading oncology companies are focusing on targeted therapies and checkpoint inhibitors, while nearly 52% of pharmaceutical pipelines include lung cancer indications, intensifying competitive innovation and strategic collaboration activities.
• Market Segmentation: Non-small cell lung cancer contributes approximately 85% of total diagnosed cases, while hospital-based treatment settings represent nearly 68% of therapeutic procedures performed across integrated cancer treatment centers and specialized oncology institutions.
• Recent Development: Around 49% of oncology research programs introduced next-generation biomarker testing advancements, while over 43% of clinical trials focused on combination immunotherapy protocols aimed at improving progression-free survival and treatment precision rates.

Lung Cancer Market Latest Trends

The Lung Cancer Market is witnessing rapid transformation driven by advancements in immunotherapy, molecular diagnostics, and AI-assisted screening technologies. More than 58% of oncology treatment centers are now implementing biomarker-guided therapies to improve treatment precision and patient survival outcomes. The Lung Cancer Market Research Report highlights increasing adoption of checkpoint inhibitors, with immunotherapy combinations used in nearly 47% of advanced-stage treatment protocols globally. Liquid biopsy utilization has increased by over 42% among diagnostic laboratories, enabling faster detection of genetic mutations associated with NSCLC. Another major trend in the Lung Cancer Market Analysis is the expansion of low-dose CT screening initiatives, which improved early-stage detection rates by approximately 33% among high-risk populations. Hospitals and oncology institutions are increasingly integrating digital pathology systems, with more than 40% of cancer centers deploying AI-driven imaging support for tumor classification and prognosis assessment. Personalized medicine continues to reshape the Lung Cancer Industry Analysis landscape as nearly 51% of pharmaceutical pipelines focus on targeted mutation therapies. The growing adoption of minimally invasive surgical procedures and robotic-assisted thoracic interventions has further strengthened procedural efficiency and post-treatment recovery rates within the Lung Cancer Market Outlook.

Lung Cancer Market Dynamics

DRIVER

"Rising adoption of targeted and immunotherapy treatments"

The increasing integration of targeted therapies and immunotherapy solutions remains a primary driver of the Lung Cancer Market Growth. Approximately 64% of oncology specialists now prioritize biomarker testing before selecting treatment protocols for NSCLC patients. The expansion of PD-1 and PD-L1 inhibitor utilization has improved progression-free survival rates among advanced-stage patients, resulting in nearly 52% higher treatment preference for immunotherapy combinations compared to traditional monotherapies. More than 46% of hospitals globally have upgraded molecular diagnostics capabilities to support genomic profiling and precision medicine integration. Lung Cancer Market Trends further indicate that EGFR mutation-targeted therapies are being adopted in over 38% of mutation-positive cases, particularly across developed healthcare systems. Increased awareness campaigns regarding early diagnosis and smoking cessation have also improved screening participation rates by approximately 29% among high-risk groups. Pharmaceutical companies continue expanding oncology pipelines, with nearly 57% of ongoing lung cancer clinical studies focusing on precision-driven therapeutic combinations. Growing healthcare infrastructure modernization and improved access to advanced oncology services are significantly contributing to treatment expansion, supporting broader commercialization opportunities across the Lung Cancer Market Forecast and Lung Cancer Market Opportunities ecosystem.

RESTRAINTS

"Limited accessibility to advanced oncology care"

Despite significant advancements, the Lung Cancer Market faces restraints related to unequal healthcare access and delayed diagnosis. Nearly 43% of patients in low-resource regions experience limited access to advanced diagnostic technologies such as PET scans, molecular testing, and liquid biopsy systems. More than 36% of healthcare facilities in developing economies lack specialized thoracic oncology departments capable of delivering integrated lung cancer treatment protocols. Delayed detection continues to impact treatment effectiveness, as approximately 61% of lung cancer cases are diagnosed at advanced metastatic stages. Lung Cancer Industry Analysis also highlights disparities in reimbursement systems, where nearly 34% of eligible patients face financial barriers associated with targeted therapies and immunotherapy procedures. Smoking-related stigma and lack of awareness contribute to lower screening participation rates among high-risk populations, reducing opportunities for early intervention. In rural healthcare systems, nearly 39% of oncology centers report shortages of trained pulmonologists, thoracic surgeons, and molecular pathology specialists. These infrastructure limitations negatively influence patient outcomes and restrict broader implementation of advanced therapeutics. Regulatory approval delays and complex clinical validation procedures further challenge product commercialization and treatment adoption across the global Lung Cancer Market Research Report landscape.

OPPORTUNITY

"Expansion of personalized medicine and AI diagnostics"

The growing adoption of personalized medicine and AI-assisted diagnostics presents major opportunities within the Lung Cancer Market Outlook. Approximately 55% of oncology institutions are investing in next-generation sequencing technologies to identify tumor-specific mutations and optimize individualized treatment planning. AI-enabled radiology systems have improved tumor detection accuracy by nearly 31%, supporting faster clinical decision-making and improved patient stratification. Lung Cancer Market Opportunities are further expanding as liquid biopsy testing gains momentum, with utilization increasing by more than 44% among diagnostic laboratories and cancer research centers. The rise of remote oncology consultation platforms has also improved treatment accessibility for underserved patient populations by approximately 28%. Pharmaceutical companies are increasingly developing combination therapies targeting KRAS, ALK, ROS1, and EGFR mutations, with nearly 49% of ongoing oncology pipelines dedicated to mutation-specific treatment approaches. Government-led cancer screening initiatives are also contributing to early-stage detection improvements, particularly in high-smoking populations. More than 41% of academic oncology institutions are collaborating with biotech companies to accelerate biomarker discovery and clinical trial innovation. These advancements continue to create substantial growth avenues across the Lung Cancer Market Insights and Lung Cancer Industry Report ecosystem.

CHALLENGE

"High complexity of treatment resistance and late-stage diagnosis"

Treatment resistance and late-stage diagnosis remain major challenges impacting the Lung Cancer Market. Approximately 57% of advanced NSCLC patients develop resistance to first-line targeted therapies within extended treatment cycles, limiting long-term therapeutic effectiveness. More than 62% of diagnosed cases continue to be identified during metastatic progression stages, reducing survival probability and narrowing treatment options. Lung Cancer Market Analysis indicates that tumor heterogeneity significantly complicates precision therapy selection, particularly among patients with multiple genetic mutations. Nearly 35% of immunotherapy-treated patients demonstrate limited response rates due to immune resistance mechanisms and biomarker variability. Healthcare providers also face operational challenges associated with integrating advanced genomic profiling into routine clinical workflows, especially in resource-constrained facilities. Over 33% of cancer centers report shortages of molecular diagnostic specialists required for accurate mutation interpretation. Additionally, rising demand for personalized oncology care is increasing pressure on healthcare systems to maintain specialized infrastructure, multidisciplinary treatment coordination, and advanced imaging capabilities. These complexities continue to create operational and clinical barriers within the Lung Cancer Market Forecast environment.

Lung Cancer Market Segmentation

The Lung Cancer Market is segmented based on treatment type and therapeutic application, with increasing emphasis on personalized treatment strategies and minimally invasive procedures. Lung Cancer Market Segmentation demonstrates growing demand for surgery, chemotherapy, radiotherapy, photodynamic therapy, and laser therapy due to rising diagnosis rates and expanding oncology infrastructure. Surgery remains widely adopted for early-stage lung tumors, while chemotherapy and radiotherapy continue dominating advanced-stage treatment protocols. Photodynamic therapy and laser therapy are gaining traction due to improved procedural precision and lower recovery complications. More than 59% of treatment selection decisions are now guided by biomarker analysis and tumor staging assessments across specialized oncology centers.

Download FREE Sample to learn more about this report.

BY TYPE

Surgery: Surgery remains one of the most significant treatment approaches within the Lung Cancer Market, particularly for early-stage non-small cell lung cancer patients. Approximately 28% of diagnosed lung cancer patients undergo surgical intervention as a primary treatment option. Lobectomy procedures account for nearly 54% of thoracic surgeries performed in specialized oncology hospitals, while minimally invasive thoracoscopic surgeries have increased by more than 36% due to faster recovery benefits and reduced hospitalization periods. Robotic-assisted thoracic surgery adoption has expanded significantly, with nearly 31% of advanced hospitals integrating robotic systems into lung tumor resections. Surgery is especially preferred among stage I and stage II patients where localized tumor removal improves long-term survival probability. More than 47% of thoracic oncology centers have integrated enhanced recovery protocols to reduce postoperative complications. Surgical treatment demand is also supported by the increasing adoption of low-dose CT screening programs, which improve early-stage detection rates among high-risk smokers. Hospital-based multidisciplinary care teams continue enhancing procedural efficiency and postoperative patient management across the Lung Cancer Market Research Report landscape.

Chemotherapy: Chemotherapy continues to represent a foundational treatment segment within the Lung Cancer Market Analysis due to its widespread application across advanced-stage and metastatic cases. Nearly 63% of lung cancer patients receive chemotherapy during at least one phase of treatment. Platinum-based chemotherapy regimens remain dominant, particularly for non-small cell and small cell lung cancer management. Combination chemotherapy protocols are utilized in approximately 49% of advanced-stage treatment plans to improve tumor response and disease control. The increasing integration of chemotherapy with immunotherapy and targeted agents has enhanced progression-free survival outcomes among high-risk patients. More than 42% of oncology centers are implementing personalized chemotherapy dosing strategies based on genomic and biomarker analysis. Chemotherapy also remains critical in adjuvant and neoadjuvant treatment settings, especially before surgical procedures and radiotherapy sessions. Supportive care advancements, including antiemetic therapies and immune-supportive medications, have reduced treatment-related complications by nearly 27%. The growing number of oncology infusion centers and expanded access to multidisciplinary cancer care continue supporting chemotherapy demand across the global Lung Cancer Industry Analysis environment.

Radiotherapy: Radiotherapy represents a highly significant treatment category within the Lung Cancer Market Outlook due to its effectiveness in localized tumor management and symptom relief. Approximately 58% of lung cancer patients undergo radiotherapy during treatment cycles, particularly for advanced-stage disease and palliative care applications. Stereotactic body radiation therapy (SBRT) adoption has increased by over 39% among early-stage inoperable patients because of its precision-focused tumor targeting capabilities. Image-guided radiotherapy systems are now implemented in nearly 44% of oncology centers to improve treatment accuracy and reduce damage to surrounding tissues. Radiotherapy is frequently combined with chemotherapy and immunotherapy in integrated treatment protocols for metastatic and recurrent lung cancer cases. Proton beam therapy utilization is also expanding gradually among specialized cancer institutions due to improved precision in thoracic tumor treatment. More than 33% of hospitals have upgraded radiation oncology infrastructure to support AI-assisted treatment planning and adaptive radiation systems. The growing prevalence of advanced-stage diagnoses and increasing awareness regarding palliative cancer care continue driving radiotherapy adoption within the Lung Cancer Market Insights landscape.

Photodynamic therapy (PDT): Photodynamic therapy (PDT) is gaining attention within the Lung Cancer Market Forecast due to its minimally invasive nature and targeted tumor destruction capabilities. Approximately 14% of specialized thoracic oncology centers now offer PDT for selected early-stage and airway-obstructing lung tumors. The therapy utilizes light-sensitive drugs activated by laser exposure to destroy malignant cells while preserving healthy tissue structures. PDT adoption has increased by nearly 22% among patients unsuitable for conventional surgery or high-dose radiotherapy procedures. Bronchoscopic-guided PDT procedures are becoming increasingly common for airway management and symptom relief in advanced lung cancer cases. More than 26% of pulmonology specialists report improved breathing outcomes and reduced airway obstruction following PDT-based interventions. The therapy is also associated with shorter recovery durations and lower systemic toxicity compared to conventional chemotherapy regimens. Technological advancements in fiber-optic delivery systems and photosensitizing agents continue supporting procedural efficiency and therapeutic precision. Increasing focus on minimally invasive oncology procedures and improved patient quality-of-life outcomes are strengthening the role of PDT within the broader Lung Cancer Market Opportunities environment.

Laser therapy: Laser therapy represents a specialized treatment segment in the Lung Cancer Industry Report, primarily utilized for airway obstruction management and tumor debulking procedures. Approximately 18% of advanced lung cancer patients experience airway narrowing complications requiring interventional bronchoscopy support, increasing demand for laser-based procedures. Nd:YAG laser systems remain among the most frequently utilized technologies due to their effectiveness in reducing obstructive tumor masses within bronchial pathways. More than 29% of thoracic intervention centers report increased utilization of laser-assisted bronchoscopic procedures for palliative care applications. Laser therapy provides rapid symptom relief, particularly for patients experiencing breathing difficulties, persistent coughing, and airway bleeding complications. Combination treatment approaches integrating laser therapy with radiotherapy and chemotherapy are becoming increasingly common among advanced-stage patients. Procedural advancements have improved treatment precision and reduced damage to surrounding tissue structures, supporting wider clinical acceptance. Nearly 24% of pulmonology specialists prefer laser-assisted airway management for patients ineligible for extensive surgery. Growing adoption of minimally invasive interventional oncology procedures continues contributing to expansion across the Lung Cancer Market Trends landscape.

BY APPLICATION

Hospitals & Clinics: Hospitals and clinics represent the dominant application segment within the Lung Cancer Market due to increasing patient admissions for diagnosis, surgery, chemotherapy, immunotherapy, and radiation procedures. Approximately 68% of lung cancer patients receive primary treatment through hospital-based oncology departments because of access to multidisciplinary care systems and advanced imaging technologies. More than 57% of hospitals globally have integrated molecular diagnostic laboratories to support precision oncology treatment selection for NSCLC and SCLC patients. Thoracic surgery units are now available in nearly 46% of tertiary healthcare institutions, improving accessibility to minimally invasive lung resection procedures. Around 52% of cancer-focused hospitals utilize AI-supported CT imaging systems for early-stage tumor identification and progression monitoring. Immunotherapy administration rates across hospital oncology networks increased by nearly 49%, driven by rising adoption of checkpoint inhibitors and targeted therapies. Outpatient oncology clinics account for approximately 38% of chemotherapy infusion procedures due to shorter treatment cycles and supportive care availability. Nearly 44% of healthcare providers expanded tele-oncology consultation services for lung cancer follow-up and treatment planning. Hospitals also remain the leading centers for palliative lung cancer care, accounting for approximately 61% of advanced-stage symptom management procedures across the Lung Cancer Market Analysis ecosystem.

Cancer Research Centers: Cancer research centers play a vital role in advancing innovation within the Lung Cancer Market Research Report landscape through biomarker discovery, clinical trial expansion, and precision medicine development. Approximately 54% of global oncology clinical trials related to lung cancer are conducted within specialized cancer research institutions. More than 48% of ongoing research programs are focused on targeted mutation therapies involving EGFR, KRAS, ALK, and ROS1 genetic alterations. Immunotherapy combination studies account for nearly 43% of active oncology research initiatives aimed at improving progression-free survival rates in advanced-stage patients. Cancer research centers have also accelerated liquid biopsy innovation, with nearly 37% of translational oncology programs integrating non-invasive genomic testing technologies. Around 41% of academic oncology institutes collaborate with pharmaceutical companies to expand biomarker-driven treatment protocols and AI-assisted diagnostics. Research-driven patient enrollment in personalized medicine studies increased by approximately 33%, supporting broader development of mutation-specific therapies. More than 46% of advanced oncology databases are maintained by dedicated cancer research facilities for genomic analysis and treatment outcome evaluation. These institutions also contribute significantly to next-generation immunotherapy advancements and targeted drug resistance studies, strengthening innovation and long-term development opportunities within the Lung Cancer Industry Analysis environment.

Laboratories: Laboratories represent a rapidly expanding application segment within the Lung Cancer Market Outlook due to growing demand for molecular diagnostics, biomarker testing, pathology analysis, and liquid biopsy procedures. Approximately 59% of lung cancer treatment decisions now involve laboratory-based genomic testing before therapy initiation. Molecular pathology laboratories account for nearly 47% of all EGFR and ALK mutation screening procedures conducted across oncology networks. Liquid biopsy testing adoption increased by over 42% among specialized cancer laboratories because of its ability to identify circulating tumor DNA with reduced procedural invasiveness. Nearly 51% of diagnostic laboratories integrated AI-powered digital pathology systems to improve tissue analysis accuracy and reduce reporting turnaround times. Companion diagnostics utilization expanded by approximately 39% as pharmaceutical companies increasingly require biomarker confirmation before targeted therapy administration. Laboratories also play a critical role in monitoring treatment resistance, with nearly 34% of advanced-stage patients undergoing repeat molecular testing during disease progression. High-throughput sequencing systems are now available in more than 29% of specialized oncology laboratories, supporting comprehensive genomic profiling for personalized medicine applications. Increasing collaborations between diagnostic laboratories and hospital oncology departments continue enhancing clinical decision-making efficiency across the Lung Cancer Market Forecast ecosystem.

Lung Cancer Market Regional Outlook

Download FREE Sample to learn more about this report.

North America

North America maintains a leading position in the Lung Cancer Market due to advanced oncology infrastructure, high screening penetration, and widespread adoption of precision medicine. Approximately 39% of global advanced immunotherapy procedures for lung cancer are conducted across North American healthcare systems. More than 64% of eligible high-risk adults have access to low-dose CT screening programs through integrated hospital networks and employer-supported insurance plans. Non-small cell lung cancer accounts for nearly 84% of diagnosed lung cancer cases across the region. Around 58% of oncology institutions have integrated AI-assisted imaging and digital pathology systems for tumor detection and treatment planning. Biomarker testing utilization exceeds 61% among advanced-stage patients receiving targeted therapy protocols. Research activity remains strong, with approximately 46% of global lung cancer clinical trials being conducted across North American research institutions and pharmaceutical networks. Hospitals and cancer centers have increasingly adopted minimally invasive thoracic surgery procedures, contributing to nearly 33% improvement in postoperative recovery outcomes. Rising smoking cessation awareness and government-supported screening initiatives continue supporting early-stage diagnosis and precision treatment expansion throughout the regional Lung Cancer Market Trends landscape.

Europe

Europe represents a highly developed region within the Lung Cancer Market Analysis ecosystem due to strong public healthcare systems, advanced cancer screening policies, and increasing adoption of targeted oncology treatments. Approximately 31% of global lung cancer diagnostic procedures are conducted across European oncology networks. More than 53% of tertiary hospitals in the region have integrated molecular profiling systems to support biomarker-driven treatment selection. Immunotherapy utilization increased by nearly 44% among advanced-stage lung cancer patients receiving combination treatment protocols. Around 37% of regional healthcare institutions now implement AI-assisted radiology platforms for early tumor identification and disease monitoring. The prevalence of smoking-related lung cancer remains significant, contributing to approximately 71% of diagnosed cases across multiple European healthcare systems. Thoracic surgery demand also continues to expand, with minimally invasive procedures accounting for nearly 42% of surgical interventions performed in specialized oncology hospitals. Cancer research collaborations between pharmaceutical companies and academic institutions increased by approximately 35%, supporting innovation in mutation-specific therapies and liquid biopsy technologies. Expanded reimbursement support for precision oncology procedures continues strengthening adoption of advanced lung cancer diagnostics and personalized medicines across the European Lung Cancer Market Outlook.

Asia-Pacific

Asia-Pacific is emerging as the fastest-expanding region in the Lung Cancer Market Forecast due to rising patient populations, increasing smoking prevalence, and expanding healthcare modernization programs. Approximately 44% of newly diagnosed lung cancer cases globally originate from Asia-Pacific healthcare systems. Urban air pollution exposure contributes significantly to rising non-smoking-related lung cancer incidence, particularly among metropolitan populations. More than 49% of regional oncology centers are investing in advanced molecular diagnostics and genomic profiling systems to improve personalized treatment selection. Government-supported cancer screening initiatives expanded by nearly 34% across high-risk populations, improving early-stage detection rates in urban healthcare networks. Around 52% of tertiary hospitals in major economies have upgraded radiotherapy and immunotherapy infrastructure to manage rising oncology workloads. Lung cancer clinical trial participation increased by approximately 39% due to expanding pharmaceutical investment and growing patient enrollment capabilities. AI-assisted pathology systems are also gaining traction, with nearly 28% of advanced oncology laboratories integrating digital imaging technologies. The increasing availability of biosimilars and targeted therapies continues improving treatment accessibility for large patient populations across the Asia-Pacific Lung Cancer Industry Report landscape.

Middle East & Africa

The Middle East & Africa region is experiencing gradual development within the Lung Cancer Market Insights landscape due to increasing healthcare investments, rising oncology awareness, and improving access to diagnostic technologies. Approximately 27% of tertiary hospitals across the region have expanded specialized oncology departments focused on thoracic cancers and precision medicine integration. Lung cancer screening participation increased by nearly 22% among high-risk smoking populations due to public health awareness campaigns and government-supported cancer initiatives. Around 31% of regional healthcare providers are integrating advanced CT imaging systems and molecular diagnostic technologies for improved tumor detection. Immunotherapy adoption increased by approximately 26% among private oncology centers offering advanced treatment protocols for metastatic lung cancer cases. More than 19% of cancer-focused hospitals have introduced robotic-assisted thoracic surgery capabilities to improve surgical precision and postoperative outcomes. Healthcare modernization programs are also contributing to increased collaboration between regional cancer centers and international pharmaceutical research organizations. Rising demand for minimally invasive oncology procedures and growing awareness regarding early-stage diagnosis continue strengthening treatment accessibility across the regional Lung Cancer Market Opportunities environment.

List of Key Lung Cancer Market Companies

• F. Hoffmann-La Roche AG
• Novartis
• PFIZER INC
• Merck＆Co.
• ELI Lilly and Company
• Sanofi
• Astrazeneca plc
• Arqule Inc
• Daiichi Sankyo co. Ltd
• Celgene
• Ventana
• Glaxosmith
• Boehringer
• Bristol-Myers Squibb
• Eisai
• AbbVie
• Pharmacyclics

Top Companies with Highest Market Share

• F. Hoffmann-La Roche AG: Approximately 24% of advanced biomarker-driven lung cancer treatment protocols involve Roche-developed targeted therapies and companion diagnostic platforms, while nearly 41% of integrated oncology laboratories utilize Roche molecular

  Lung Cancer Market Report Coverage

  REPORT COVERAGE	DETAILS
  Market Size Value In	USD 38955.71 Million in 2026
  Market Size Value By	USD 102716.3 Million by 2035
  Growth Rate	CAGR of 11.38% from 2026 - 2035
  Forecast Period	2026 - 2035
  Base Year	2025
  Historical Data Available	Yes
  Regional Scope	Global
  Segments Covered
  	By Type Surgery Chemotherapy Radiotherapy Photodynamic therapy (PDT) Laser therapy
  	By Application Hospitals & Clinics Cancer Research Centers Laboratories